HIV/AIDS Therapy
New HIV/AIDS therapy research has been reported by scientists at University of Pennsylvania, Department of Microbiology
Published in AIDS Weekly, April 9th, 2007
A new study, "Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors," is now available. "The clinical use of the human immunodeficiency virus (HIV) fusion inhibitor enfuvirtide (ENF) can select for drug-resistant HIV-1 strains bearing mutations in the HR1 region of the viral envelope (Env) protein. We analyzed the properties of multiple Env proteins isolated from five patients who experienced an initial decline in viral load after ENF therapy followed by subsequent rebound due to emergence of ENF-resistant HIV-1," researchers in the United States report.
"Prior to ENF therapy, each...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2007-04-09)
More Articles from AIDS Weekly
- HIV/AIDS
Community-based measures fail to reduce HIV levels, new study shows - HIV/AIDS
Cornell researcher helping develop quick, cheap HIV/AIDS test - HIV/AIDS
Exclusive breastfeeding lowers babies' risk of postnatal infection with HIV - HIV/AIDS
AIDS Advocates March in India, Call for Universal Access to Lifesaving Treatment - HIV/AIDS
AIDS Healthcare Foundation and Vietnam's Haiphong Provincial AIDS Control Center Unveil New Partnership; Dedicate Groundbreaking AIDS Care Center - HIV/AIDS
AIDS Vaccine Advocacy Coalition Calls for Strategic Leadership and Urgency in the Implementation of Male Circumcision for HIV Prevention - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
